The Europe Metagenomics Market would witness market growth of 13.1% CAGR during the forecast period (2022-2028).
Read lengths were considerably less than the normal Sanger sequencing read length of 750 bp, but Illumina technology is rapidly approaching this standard. Nonetheless, this constraint is mitigated by the vastly increased quantity of sequence reads. In 2009, pyro-sequenced metagenomes produce 200–500 megabases and Illumina platforms produce 20–50 gigabases, however, both outputs have expanded by orders of magnitude over the past few years.
An innovative method for guiding microbial genome assembly combines shotgun sequencing and chromosomal conformation capture (Hi-C), which assesses the closeness of any two DNA sequences within the same cell. Long read sequencing technologies, such as PacBio RSII and PacBio Sequel by Pacific Biosciences and Nanopore MinION, GridION, and PromethION by Oxford Nanopore Technologies, are an additional option for obtaining long shotgun sequencing reads that should facilitate the assembly procedure.
The DNA sequence data from genomic and metagenomic are virtually identical, although genomic sequence data provides greater coverage, whilst metagenomic data is typically extremely non-redundant. In addition, the rising use of second-generation sequencing technology with short read lengths will render a significant portion of future metagenomic data susceptible to mistakes. These variables, when combined, make the assembling of metagenomic sequence reads into genomes challenging and unpredictable.
The United Kingdom is capable of dominating the health technology market. They already have some of the most renowned health technology firms in the world, which contribute to creating inventions and enhance the country's international status as a scientific and research powerhouse. In addition, it can establish an ecosystem that consistently develops the most advanced transferrable health technologies, as well as techniques and insights that can improve health outcomes.
The Germany market dominated the Europe Metagenomics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $191.1 Million by 2028.The UK market is anticipated to grow at a CAGR of 12.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 13.9% during (2022 - 2028).
Based on Workflow, the market is segmented into Sequencing, Pre-sequencing and Data Analysis. Based on Product, the market is segmented into Kits & Reagents, Sequencing & Data Analytics Services and Software. Based on Technology, the market is segmented into Shotgun Sequencing, 16S Sequencing, Whole Genome Sequencing and Others. Based on Application, the market is segmented into Environmental, Clinical Diagnostics, Drug Discovery, Biotechnology, Food & Nutrition and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Metagenomics Market will Hit $3.2 Billion by 2028, at a CAGR of 13.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Novogene Co., Ltd., Promega Corporation, Qiagen N.V., Takara Bio, Inc. (Takara Holdings Inc.), Oxford Expression Technologies Ltd., and F. Hoffmann-La Roche Ltd.
By Workflow
By Product
By Technology
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
